A Targeted Therapeutic for Cancer

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. AEG35156 has completed its first Phase 2 trial in refractory AML patients and will shortly be enrolling in a randomized Phase 2 study in the same indication. Other enrolling studies include a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society, and a Phase 2 randomized combination study with sorafenib in first-line hepatocellular carcinoma being conducted in Hong Kong.

November 19, 2009
Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the treatment of Acute Myeloid Leukemia (AML)
   
July 31, 2008
AEGERA INITIATES A FIFTH PHASE 1 and 2 CLINICAL TRIAL FOR AEG35156